<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398983</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0358</org_study_id>
    <nct_id>NCT00398983</nct_id>
  </id_info>
  <brief_title>Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Randomized Study of Decitabine Versus Observation or Continued Standard Chemotherapy as Maintenance Therapy for Adults With Unfavorable Risk AML in First Complete Remission (CR) or Adults With Relapsed AML in Second or Greater CR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to find out whether continued therapy with decitabine
      after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the
      remission and prevent relapse of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methylation is a change that occurs to DNA that has an effect on how genes are used in human
      cells. It is very common in leukemias for methylation to happen abnormally. Decitabine is a
      new drug that blocks DNA methylation. At low doses (such as those used in this study),
      decitabine blocks proteins important in abnormal DNA methylation, which may, in turn, allow
      leukemia cells to die and disappear.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of 2 groups. Group 1 will receive decitabine about every 4-8
      weeks to see whether this drug is useful in lengthening the duration of remission in patients
      like you. Group 2 will not receive the study drug.

      If you are assigned to Group 1, the drug will be given over about 1 hour through a peripheral
      or central catheter every day for 5 days. A peripheral or central venous catheter is a
      sterile flexible tube that will be placed into a large vein while you are under local
      anesthesia. Your doctor will explain this procedure to you in more detail, and you will be
      required to sign a separate consent form for this procedure. You will receive the study drug
      for 5 days per study &quot;cycle&quot;. Each cycle will be about 4-8 weeks. You must receive your study
      drug at M. D. Anderson Cancer Center.

      You may remain on study for up to 12 Cycles. You will be taken off study if the disease gets
      worse, your doctor feels it is in your best interest, or you develop intolerable side
      effects.

      During the study, blood (about 2 tablespoons) will be drawn for routine tests every week
      during the first month and then every 2-4 weeks after that. You will also have a bone marrow
      examination aspirate/biopsy every 3-6 months to make sure that your disease remains in
      remission.

      If you are assigned to Group 2, you will continue under the care of your doctor. This will
      include study visits and having a bone marrow examination aspirate/biopsy every 3-6 months up
      to one year after randomization to make sure that the disease remains in remission.

      Once you are off study, blood (about 2 tablespoons) will be drawn and you will have a bone
      marrow biopsy/aspirate.

      This is an investigational study. Decitabine is FDA-approved and is commercially available.
      It is not FDA approved for this usage, and it has been authorized for use in research only.
      Up to 100 patients will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Relapse-Free Response at 1 Year</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Relapse free response defined an absence of relapse at one year of follow up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine 20 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/m^2 intravenous (IV) daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Study Drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continue current therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>20 mg/m^2 IV over 1 hour daily for 5 days</description>
    <arm_group_label>Decitabine 20 mg/m^2</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (greater than 18 years) with acute myelogenous leukemia (AML) by World
             Health Organization (WHO) criteria (greater than 20% blasts) and unfavorable risk
             cytogenetics (including intermediate and poor risk categories) in first CR or complete
             remission without full platelet recovery (CRp)

          -  Adult patients (greater than 18 years) in second or subsequent Complete Response (CR)
             (or CRp)

          -  Patients in first CR (or CRp) may have received any induction chemotherapy regimen;
             they may have received post-remission consolidation therapy (except for transplant)
             prior to inclusion in this protocol

          -  Patients in 2nd or subsequent CR (or CRp) may have received any appropriate salvage
             regimen before achieving CR and may have received further therapy before inclusion

          -  Performance status of 0, 1, or 2

          -  Adequate organ function with creatinine less than or equal to 2.0 mg/dL, bilirubin
             less than or equal to 3.5 mg/dL and aspartate aminotransferase (AST or SGOT) and
             alanine aminotransferase (ALT or SGPT) less than or equal to 3 times institutional
             upper limit of normal

        Exclusion Criteria:

          -  Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative
             pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous
             surgical sterilization

          -  Known to be HIV+

          -  Active and uncontrolled disease/infection as judged by the treating physician

          -  Unable or unwilling to sign the consent form

          -  No other investigational therapy within the past 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi-Kashani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <results_first_submitted>January 25, 2013</results_first_submitted>
  <results_first_submitted_qc>January 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2013</results_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Remission</keyword>
  <keyword>Decitabine</keyword>
  <keyword>Maintenance Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 8/28/2006 to 10/15/2009. All patients registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the fifty participants registered, forty-five participants were evaluable. Twenty were randomized to Decitabine 20 mg/m^2, and twenty-five were randomized to no study drug. Five participants withdrew consent or developed complications before assignment of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Decitabine 20 mg/m^2</title>
          <description>20 mg/m^2 intravenous (IV) daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>No Study Drug</title>
          <description>Continue current therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decitabine 20 mg/m^2</title>
          <description>20 mg/m^2 intravenous (IV) daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>No Study Drug</title>
          <description>Continue current therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="24" upper_limit="79"/>
                    <measurement group_id="B2" value="53" lower_limit="31" upper_limit="72"/>
                    <measurement group_id="B3" value="57" lower_limit="24" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Relapse-Free Response at 1 Year</title>
        <description>Relapse free response defined an absence of relapse at one year of follow up.</description>
        <time_frame>Baseline to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Decitabine 20 mg/m^2</title>
            <description>20 mg/m^2 intravenous (IV) daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>No Study Drug</title>
            <description>Continue current therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse-Free Response at 1 Year</title>
          <description>Relapse free response defined an absence of relapse at one year of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five years, eight months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Decitabine 20 mg/m^2</title>
          <description>20 mg/m^2 intravenous (IV) daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>No Study Drug</title>
          <description>Continue current therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farhad Ravandi-Kashani, MD / Associate Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-745-0394</phone>
      <email>eharrison@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

